跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
The Promise and the Puzzle

Bold claims, small patient count

2 / 3
Look at the two columns together, because the point is the contrast, not either side alone. On the left are the claims: faster discovery, molecules no chemist would have drawn, failures predicted before expensive testing. On the right is what has actually reached patients: a handful of candidates in early human trials, and no AI-originated drug yet in routine clinical use. Notice that the left column describes the design stage, while the right column counts completed journeys. Those are different things, and the distance between them is what we are going to explain.
0:00 / 0:00

The public claims about AI in drug discovery are broad. They include discovering new drug candidates in a fraction of the usual time, designing molecules that human chemists would not have thought of, predicting which candidates will fail before expensive testing begins, and eventually making drug development cheaper and more reliable.

The observable reality is narrower. A small number of drug candidates that originated from AI-driven design have entered human testing, mostly in early-stage trials. Entering a trial is not the same as succeeding in one, and succeeding in an early trial is not the same as becoming a medicine that doctors prescribe. As of the mid-2020s, no AI-originated drug had become a standard treatment in routine clinical use.

Both columns in the comparison are real. The claims describe what the tools can do at the design stage. The reality describes how few of those designs have completed the long path to a patient. The gap between the two columns is the puzzle this course sets out to explain.

上一页2 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion